Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jilin Province Huinan Changlong Bio-pharmacy Co's earnings before interest and taxes (EBIT) for the
six
months ended in Jun. 2026 was HK$176 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was HK$332 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Jilin Province Huinan Changlong Bio-pharmacy Co's annualizedROC % for the quarter that ended in Jun. 2026 was 14.25%.
Jilin Province Huinan Changlong Bio-pharmacy Co's annualizedROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 122.69%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Jilin Province Huinan Changlong Bio-pharmacy Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 130.10%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jilin Province Huinan Changlong Bio-pharmacy Co EBIT Related Terms
Jilin Province Huinan Changlong Bio-pharmacy Co EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jilin Province Huinan Changlong Bio-pharmacy Co EBIT Chart
Jilin Province Huinan Changlong Bio-pharmacy Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Jilin Province Huinan Changlong Bio-pharmacy Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jilin Province Huinan Changlong Bio-pharmacy Co EV-to-EBIT vs Drug Manufacturers Industry
Jilin Province Huinan Changlong Bio-pharmacy Co EBIT Calculation
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$332 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jilin Province Huinan Changlong Bio-pharmacy Co (HKSE:08049) has a EBIT of HK$332 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Jilin Province Huinan Changlong Bio-pharmacy Co.
Is Jilin Province Huinan Changlong Bio-pharmacy Co's EBIT too high?
Jilin Province Huinan Changlong Bio-pharmacy Co's current EBIT is HK$332 Mil. Overall, Jilin Province Huinan Changlong Bio-pharmacy Co has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jilin Province Huinan Changlong Bio-pharmacy Co's EBIT compare to ZTS?
Jilin Province Huinan Changlong Bio-pharmacy Co's EBIT of HK$332 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Jilin Province Huinan Changlong Bio-pharmacy Co. Jilin Province Huinan Changlong Bio-pharmacy Co's current EBIT is HK$332 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jilin Province Huinan Changlong Bio-pharmacy Co stock overvalued right now?
Based on GuruFocus' analysis, Jilin Province Huinan Changlong Bio-pharmacy Co (HKSE:08049) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$1.82, compared to a current price of HK$2.35 — trading 29.1% above its estimated fair value. The current EBIT is HK$332 Mil. Jilin Province Huinan Changlong Bio-pharmacy Co's overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Jilin Province Huinan Changlong Bio-pharmacy Co (HKSE:08049), the current EBIT is HK$332 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jilin Province Huinan Changlong Bio-pharmacy Co (HKSE:08049) Overvalued in 2026?
Based on GuruFocus' analysis, Jilin Province Huinan Changlong Bio-pharmacy Co stock appears to be overvalued.
The current stock price of HK$2.35 is trading 29.1% above its estimated GF Value™ of HK$1.82.
GuruFocus considers Jilin Province Huinan Changlong Bio-pharmacy Co to be Modestly Overvalued.
Key valuation signals for HKSE:08049:
EBIT: HK$332 Mil
GF Value™: HK$1.82 vs. price of HK$2.35 (29.1% above fair value)
No single metric tells the full story. See the HKSE:08049 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd is principally engaged in the manufacture and distribution of Chinese medicines and pharmaceutical products in the PRC under the brand names of Changlong and Qing Tong. The company has only one business segment. It generates revenue from the Sales of Chinese medicines and pharmaceutical products. Geographically, it derives its entire revenue from the PRC.
74GF Score
Get the complete analysis for HKSE:08049
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08049 has been successfully added to your 
